About Jixing Pharmaceuticals

CORXEL is developing investigational new drugs JX09 and JX10 for the treatment of hypertension and acute ischemic stroke, addressing the urgent need for effective therapies in cardiometabolic diseases. The company leverages a global clinical development network to expedite trials and deliver life-changing treatments to patients worldwide.

```xml <problem> Cardiovascular and metabolic diseases are leading causes of death and disability worldwide, yet significant unmet needs remain in their prevention and treatment. Current therapies for conditions like hypertension and acute ischemic stroke often have limitations in efficacy or accessibility, highlighting the need for innovative treatment solutions. </problem> <solution> CORXEL is a global biotechnology company focused on developing novel therapies for cardiometabolic diseases. Their lead assets, JX09 and JX10, are investigational new drugs targeting hypertension and acute ischemic stroke, respectively. CORXEL aims to expedite clinical trials and deliver breakthrough treatments to patients by leveraging a global clinical development network and a team of experienced professionals in both the United States and China. The company is committed to conducting high-quality, efficient clinical studies to address the urgent needs of patients with cardiometabolic disorders. </solution> <features> - JX09: An investigational new drug for the treatment of hypertension. - JX10: An investigational new drug for the treatment of acute ischemic stroke. - Global clinical development network providing access to key opinion leaders, clinical study sites, and patients in the US and China. - Experienced team of medical, clinical, CMC (Chemistry, Manufacturing, and Controls), registrational, and business development professionals. </features> <target_audience> The primary target audience includes patients suffering from hypertension and acute ischemic stroke, as well as healthcare providers and clinical researchers in the field of cardiometabolic diseases. </target_audience> ```

What does Jixing Pharmaceuticals do?

Where is Jixing Pharmaceuticals located?

Jixing Pharmaceuticals is based in Shanghai, China.

When was Jixing Pharmaceuticals founded?

Jixing Pharmaceuticals was founded in 2019.

Location

Shanghai, China

Founded

2019

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Jixing Pharmaceuticals

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

jixing.com

Founded 2019 – Shanghai, China

Funding

No funding information available.

Team

No team information available.

Company Description

Problem

Cardiovascular and metabolic diseases are leading causes of death and disability worldwide, yet significant unmet needs remain in their prevention and treatment. Current therapies for conditions like hypertension and acute ischemic stroke often have limitations in efficacy or accessibility, highlighting the need for innovative treatment solutions.

Solution

CORXEL is a global biotechnology company focused on developing novel therapies for cardiometabolic diseases. Their lead assets, JX09 and JX10, are investigational new drugs targeting hypertension and acute ischemic stroke, respectively. CORXEL aims to expedite clinical trials and deliver breakthrough treatments to patients by leveraging a global clinical development network and a team of experienced professionals in both the United States and China. The company is committed to conducting high-quality, efficient clinical studies to address the urgent needs of patients with cardiometabolic disorders.

Features

JX09: An investigational new drug for the treatment of hypertension.

JX10: An investigational new drug for the treatment of acute ischemic stroke.

Global clinical development network providing access to key opinion leaders, clinical study sites, and patients in the US and China.

Experienced team of medical, clinical, CMC (Chemistry, Manufacturing, and Controls), registrational, and business development professionals.

Target Audience

The primary target audience includes patients suffering from hypertension and acute ischemic stroke, as well as healthcare providers and clinical researchers in the field of cardiometabolic diseases.